Literature DB >> 34593255

Prevention of Vertical Transmission of Hepatitis B Within a North Carolina Hospital System.

Wesley Sayre1, Peyton Thompson2.   

Abstract

PURPOSE: Hepatitis B virus (HBV) is a major contributor to liver-related disease globally. Vertical transmission of hepatitis B can lead to devastating outcomes in neonates, making prevention of transmission essential. Fortunately, prevention is possible with evidence-based interventions via guidelines from the American Association for the Study of Liver Diseases (AASLD). The purpose of this study was to assess compliance with AASLD guidelines at a tertiary referral hospital in North Carolina, and to suggest future quality improvement initiatives to improve care for this population.
METHODS: We performed a retrospective chart review, including data from all HBV-positive birthing persons at the tertiary referral hospital from April 1, 2014 through December 31, 2019. Data was then compared to AASLD guidelines.
FINDINGS: We identified 99 birthing persons who were hepatitis B positive at time of birth. Of the 99 birthing person/neonate dyads, nearly all infants received appropriate and timely HBV birth dose vaccination and HBIG administration. Risk status of HBV-infected birthing persons was completed in only 58% of this population. Of the individuals who were found to be high risk for vertical transmission of HBV, 75% received antiviral prophylaxis. IMPLICATIONS: This study provides a current assessment of prevention practices in vertical transmission of HBV compared to published guidelines. The tertiary hospital studied generally implemented AASLD recommendations for prevention of vertical transmission. However, our data revealed that appropriate risk status testing could be improved. With improvement in risk status testing, antiviral prophylaxis can be provided, decreasing the likelihood of breakthrough HBV vertical transmission. Follow-up for HBV-infected birthing persons and HBV-exposed neonates is also a priority. Achieving full compliance with AASLD guidelines to prevent vertical transmission of HBV is possible, and we provide structure for quality improvement initiatives that aim to accomplish this.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  hepatitis B vaccination; hepatitis B virus; prevention; vertical transmission

Mesh:

Substances:

Year:  2021        PMID: 34593255      PMCID: PMC8691857          DOI: 10.1016/j.clinthera.2021.08.012

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  4 in total

1.  Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein.

Authors:  Shuqin Zhang; Shan Gao; Man Zhao; Yunxia Liu; Yanan Bu; Qiulei Jiang; Qiang Zhao; Lihong Ye; Xiaodong Zhang
Journal:  Cancer Lett       Date:  2017-02-09       Impact factor: 8.679

2.  Hepatitis B in childhood: An update for the paediatrician.

Authors:  L T Yeung; E A Roberts
Journal:  Paediatr Child Health       Date:  2001-11       Impact factor: 2.253

3.  AASLD guidelines for treatment of chronic hepatitis B.

Authors:  Norah A Terrault; Natalie H Bzowej; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; M Hassan Murad
Journal:  Hepatology       Date:  2015-11-13       Impact factor: 17.425

Review 4.  Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis.

Authors:  Robert S Brown; Brian J McMahon; Anna S F Lok; John B Wong; Ahmed T Ahmed; Mohamed A Mouchli; Zhen Wang; Larry J Prokop; Mohammad Hassan Murad; Khaled Mohammed
Journal:  Hepatology       Date:  2015-11-13       Impact factor: 17.425

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.